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Allelic loss at chromosome 13q12 -q13 is associated with poor prognosis in
familial and sporadic breast cancer
J van den Berg, 0 Johannsson, S Hakansson, H Olsson and A Borg
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Summary Loss of heterozygosity (LOH) was analysed in 84 primary tumours from sporadic, familial and
hereditary breast cancer using five microsatellite markers spanning the chromosomal region 13ql2-ql3 which
harbours the BRCA2 breast cancer susceptibility gene, and using one other marker located within the RBI
tumour-suppressor gene at 13ql4. LOH at the BRCA2 region was found in 34% and at RBI in 27% of the
tumours. Selective LOH at BRCA2 occurred in 7% of the tumours, whereas selective LOH at RBI was
observed in another 7%. Moreover, a few tumours demonstrated a restricted deletion pattern, suggesting the
presence of additional tumour-suppressor genes both proximal and distal of BRCA2. LOH at BRCA2 was
significantly correlated to high S-phase values, low oestrogen and progesterone receptor content and DNA
non-diploidy. LOH at BRCA2 was also associated, albeit non-significantly, with large tumour size and the
ductal and medullar histological types. No correlation was found with lymph node status, patient age or a
family history of breast cancer. A highly significant and independent correlation existed between LOH at
BRCA2 and early recurrence and death. LOH at RBI was not associated with the above mentioned factors or
prognosis. The present study does not provide conclusive evidence that BRCA2 is the sole target for deletions
at 13ql2-ql3 in breast tumours. However, the results suggest that inactivation of one or several tumour-
suppressor genes in the 13q12 -q13 region confer a strong tumour growth potential and poor prognosis in both
familial and sporadic breast cancer.
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The study of hereditary cancer syndromes and identification
of mutated predisposing genes has provided clues to the
initial genetic events in carcinogenesis, some of which may
also be involved in sporadic forms of the diseases (Knudsen,
1993). This model may also be used in elucidating the
multifactorial cause of breast cancer, a disease in which
genetic components have been implicated but in which
precursor lesions are hard to define and analyse.
A major breast and ovarian cancer susceptibility gene,
BRCAI on chromosome 17q21, has been identified by
positional cloning (Miki et al., 1994). The frequent finding
of putative loss-of-function germline mutations in breast/
ovarian cancer families and the loss of the wildtype allele in
corresponding tumours suggests that BRCA1 is a tumour-
suppressor gene inactivated by classical mechanisms. How-
ever, although loss of heterozygosity (LOH) of the 17q21
region and a reduced BRCAJ expression is observed in
invasive sporadic breast cancer (Thompson et al., 1995),
somatic BRCA1 mutations are infrequent in breast and
ovarian tumours (Futreal et al., 1994; Merajver et al., 1995),
suggesting that the role of BRCAI in tumorigenesis may be
restricted to the hereditary form of the disease.
A second major breast cancer susceptibility gene, BRCA2,
was recently identified at chromosome 13ql2, proximal to the
retinoblastoma (RB]) gene at 13ql4 (Wooster et al., 1995;
Tavtigian et al., 1996). The findings of frequent LOH at
chromosome 13q in breast cancer (Varley et al., 1989) have
previously been assumed to be owing to the involvement of
the RB] gene in tumour development. However, in an earlier
study (Borg et al., 1992), we found an incomplete correlation
between LOH and loss of RBI expression, suggesting that
other adjacent genes might also be targets for deletions. This
presumption was subsequently reinforced by the isolation of
Brush-], a gene proximal to RB1 on 13ql2-ql3 which
manifests reduced expression in tumours with LOH (Schott et
al., 1994). Thus, three or more potential tumour-suppressor
genes may reside in the 13ql2-ql4 region, supporting the
theory that a complexity of gene rearrangement exists in
tumours. The present study was undertaken to analyse the
LOH in microsatellite markers flanking the BRCA2 locus and
its correlation to prognostic factors in tumours from both
familial and sporadic breast cancer.
Materials and methods
Patients and tumours
Eighty-four patients diagnosed for primary breast cancer in
the age range 26-80 years were included. Cases were
included into one of three categories according to patient
family history of cancer, as obtained from clinical records
and patient interviews: (1) Hereditary breast cancer (n=30),
three or more first- or second-degree relatives (including the
index case) with breast or ovarian cancer, at least one of
which had an early age (<50 years) of onset; (2) Familial
breast cancer (n = 16), two first- or second-degree relatives
(including the index case) with breast or ovarian cancer, at
least one before the age of 50 or, alternatively, three or more
cases over the age of 50; (3) Sporadic breast cancer (n =39),
no cancer of any kind in first- or second-degree relatives of
the index case. Data on tumour size, lymph node status,
histological type and clinical follow-up were obtained from
patient records. A subset of the familial and hereditary cases
included in the present study has been investigated for
BRCAI and BRCA2 germline mutations and/or linkage
(Johannsson et al., 1996; Hakansson et al., submitted).
Tumours were analysed for oestrogen (ER) and progester-
one receptors (PgR) with enzyme immunoassays and for
DNA ploidy and S-phase fraction with DNA flow cytometry,
according to previously described protocols (Fern6 et al.,
1992). ERBB2 and 1 1q13 (INT2) amplifications were assessed
by slot blot analysis on extracted tumour DNA (Borg et al.,
1991).
PCR microsatellite analysis
The polymerase chain reaction (PCR) was used to detect
allelic imbalance (designated here as LOH) at polymorphic
microsatellite markers by comparing the allelic pattern in
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tumour and blood DNA. Six chromosome 13q markers were
analysed using primers with published sequence (Gyapay et
al., 1994) purchased from Research Genetics (Huntsville, AL,
USA). The markers were, from centromere to telomere,
D13S290, D13S260, D13S267, D13S219, D13S263 and
D13S153. The first three markers reside within the 6 cM
BRCA2 region at chromosome 13q12-q13 as initially defined
(Wooster et al., 1994), while D13S153 lies within the RB]
gene at 13q14. The same patient material was also analysed
for LOH at markers on chromosome 16q. The markers were,
from telomere to centromere, D16S261, S16S308, D16S186,
D16S301, D17S318, D16S305 and D16S303 (Research
Genetics). The PCR mixture (30 4ul) contained 10 mM Tris-
HCl (pH 8.3), 50 mM potassium chloride, 1.1-2.5 mM
magnesium chloride, 0.13 kiM of each primer, 20 /uM of
dNTPs, 0.75 units of Taq polymerase (Boeringer Man-
nheim) and 80 ng of genomic DNA. The forward primer
had been radiolabelled with T4 polynucleotide kinase
(Promega) and [32P]ATP (>5000 Ci mmol-1, Amersham).
The PCR was carried out in an OmniGene thermocycler
(Hybaid) and consisted of one cycle of 4 min at 93°C,
followed by 28-32 cycles of 1 min at 93°C, 1 min at 52-
68°C, 1 min at 72°C, followed by one cycle of 5 min at 72°C.
An aliquot of 1-8 pl PCR product was mixed with
denaturing loading buffer (95% deionised formamide,
10 mm sodium hydroxide, 0.05% bromophenol blue, 0.05%
xylene cyanol), heated for 5 min at 95°C, cooled on ice and
loaded (4 ,ll) on 0.4 mm thick, preheated and denaturing
(8 M urea) 6% polyacrylamide gels for electrophoresis at 45-
50°C for 4 h. The gels were transferred to chromatography
paper, and autoradiographed (by exposing radiographs for
10-72 h at -700C). In order to accurately compare the band
intensities, care was taken to use approximately equal
concentrations of PCR products within each analysed
tumour/blood pair.
Statistical analysis
The correlation between dichotomised variables were
compared by chi-square and Pearson analysis. Differences
in survival between subgroups of patients were compared
with the log-rank test, and the survival curves were computed
according to the method of Kaplan and Meier. Multivariant
survival analysis was done according to the Cox proportional
hazard model. All computations were executed with the Stata
software (Stata Corporation, Release 3.1, 6th edition, College
Station, TX, USA).
Results
Frequency and pattern ofLOH
Forty percent of all 84 tumours manifested LOH for at least
one informative marker on chromosome 13q. Most often
these alterations involved both the BRCA2 (D13S290,
D13S260 and D13S267) and the RBI (D13S153) loci.
LOH at the BRCA2 region was found in 34% of 83
informative tumours and at RBI in 27% of 60 informative
tumours. Six tumours manifested LOH limited to markers
within the BRCA2 region, whereas LOH at RBI was found
in another six tumours with retained heterozygosity at
BRCA2. A striking feature of the deletions found on
chromosome 13q was that the majority exhibited the near
complete loss of one allele, compared with the often more
partial allelic loss of markers from chromosome 16q (data
not shown).
A few tumours manifested a restricted pattern of LOH
within the BRCA2 region (Figure 1). In tumour no.6723
from a hereditary breast cancer, clear LOH was evident at
D13S260 but not at D13S219 (D13S267 and D13S153 being
uninformative), in keeping with the more selective LOH in
the BRCA2 region. Similarly, in tumour no.7928 from a
sporadic breast cancer, LOH was manifest at D13S267, but
not at D13S219 or D13S153 (D13S260 being uninformative).
However, in tumour no.8649 from a hereditary breast
cancer, LOH was observed at D13S290 but not at
D13S260, D13S267 or D13S153, suggesting that a gene
proximal to BRCA2 may be involved. Moreover, in tumour
no.6814 from a familial breast cancer (Figure 1), LOH was
found at D13S219 and D13S263, but not for markers at the
#6814
0
Brush-i
D13S290 0
D13S260
BRCA2 O
D13S267
D13S219 0
D13S263-,,_. D13S153_ _0
RBI
0
0
0
0
0
0
0
0
0
0
0
0
0
0o.
0
D13S290
/
0/ D3S6
oD1S267 0 0
@0
o * US1
0 0
0' 0\
59 0 \ \D13S263
D13S153
T N
Figure 1 The pattern of loss of heterozygosity (LOH) at chromosome 13q12 -q14 in five individual breast tumours. 0, LOH; 0, retained
heterozygosity; 0, not informative. Autoradiograms are shown for tumour no.6814 manifesting complete LOH at D13S219 and partial LOH
at D13S263 but retained heterozygosity at D13S267 and more proximal markers, as well as at RBI.
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IBRCA2 or RB1 loci, suggesting the presence of an
additional target gene distal to D13S267 and BRCA2 but
proximal to RBI.
Correlation to other clinical and tumour characteristics
A strongly significant correlation was found between LOH
at BRCA2 (i.e. LOH at one or more of D13S290, D13S260
and D13S267) and a high rate of proliferation (S-phase
fraction, SPF). More than 80% of the most rapidly
proliferating tumours manifested LOH at BRCA2, com-
pared with merely 8% within the group of slowly growing
tumours (Table I). The mean SPF in the group showing
LOH was 12.5% (median 12%), whereas the corresponding
percentage in the group without LOH was as low as 5.8
(median 5.1%). A similar trend, but without statistical
significance, was found between LOH at RBI and the level
of S-phase fraction. A significant relationship was also
found between LOH at BRCA2 and lack of ER and PgR
Table I Relationship between loss of heterozygosity at BRCA2 or
RBI, and other clinicopathological and biological/genetic factors in
breast cancer
BRCA2 RB1
Variable n LOH % P-value n LOH % P-value
Total 83 34 60 27
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expression. Moreover, allelic loss at BRCA2, but not at
RBI, was associated with DNA non-diploidy. However, no
correlation was found to LOH at chromosome 16q or to
amplification of the ERBB2 gene or the chromosomal region
11q13. Ductal tumours manifested a slightly higher
frequency of LOH at both BRCA2 and RBI, compared
with lobular tumours, although the number of lobular
tumours was too low for reliable comparison to be made.
Interestingly, LOH at BRCA2 was observed in four of five
medullar tumours, three of which were informative at RBI
and manifested retained heterozygosity.
There was no difference in the frequency ofLOH at BRCA2
or RBI in tumours from patients with either sporadic, familial
or hereditary disease, nor in respect of different age groups
(Table I). A strong association between LOH at BRCA2 and
high SPF values was observed in all three groups of breast
cancer, mean SPF values in tumours manifesting LOH being
13.2% (sporadic) 18.5% (familial) and 11.2% (hereditary),
compared with 5.2%, 5.7% and 6.1%, respectively, in the
groups of tumours with retained heterozygosity at BRCA2.
Interestingly, the six tumours with LOH limited to the BRCA2
locus were all from sporadic breast cancer, whereas the six
tumours with LOH at RB] (but with retained heterozygosity
at BRCA2) were ofmixed origin in respect offamily history of
breast cancer. Finally, while there was a similar high frequency
of LOH in node-negative and node-positive tumours, a trend
was seen towards a higher rate of LOH at BRCA2 in tumours
of larger size.
Type of disease
Sporadic
Familial
Hereditary
Age
<40 years
40-50 years
>50 years
Node status
0
1-3
>3
Tumour size
<20 mm
>20
Histology type
Ductal
Lobular
Medular
Miscellaneous
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<25 fmol mg
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S-phase fraction
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31
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NS 17 24
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3
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Correlation to prognosis
A strongly significant correlation was found between LOH at
NS BRCA2 and a shortened recurrence-free survival (Figure 2); a
significant relationship being found also to overall survival
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Figure 2 Disease-free survival in 83 breast cancers categorised
after LOH at the BRCA2 locus (a) and in 60 breast cancers
categorised after LOH at the RBI gene (b).
aCombined data from markers: D16S261, D16S308, D16S186,
D16S301, D16S318, D16S305 and D16S303. NS, non-significant.
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Table II Multivariate disease-free survival analysis of 77 breast cancers
Univariate Multivariate
Variable P-value P-value RR 95% Cl
Node status 0 vs 1-3 NS NS
0 vs 4+ 0.071 NS
Tumour size <20 vs >20 mm NS NS
Age <50 vs >50 NS NS
ER < 10 vs > 10 fmol mg-, 0.022 NS
PgR < 10 vs > 10 fmol mg-' 0.070 NS
BRCA2 No LOH vs LOH 0.001 0.016 4.1 1.3-13
NS = not significant (P-values <0.05 are shown).
(P=0.0041). This correlation was less evident for cases with
LOH at RBI; in fact none of the six patients with tumours
manifesting LOH limited to RBI had recurring disease or had
died. However, the worst prognosis was found in the group
of cases with LOH at both BRCA2 and RBI, more than half
(11 of 20) of which had recurring disease within the median
follow-up period of 38 months, compared with one of six
patients with LOH solely at BRCA2. LOH at chromosome
16q was not related to either shortened disease-free or overall
survival.
Multivariate disease-free survival analyses were also
performed, including as covariates LOH at BRCA2, lymph
node status, tumour size, age, ER and PgR status. LOH at
BRCA2 was found to be an independent prognostic factor
(Table II).
Discussion
Allelic deletion and loss of heterozygosity constitutes the
second event in the genetic two-hit model, according to which
both copies of a tumour-suppressor gene are inactivated
(Knudsen et al., 1993). Consequently, the findings of a high
frequency of LOH at the BRCAI breast cancer susceptibility
gene on chromosome 17q21 both in hereditary and sporadic
breast tumours are strongly suggestive of a general
involvement of this putative tumour-suppressor gene in
breast tumorigenesis. However, while the unmasking of a
recessive BRCA] mutation by deletion of the remaining
wildtype allele holds to be true in hereditary BRCAI-linked
tumours (Smith et al., 1992; Johannsson et al., 1996), the
evidence for the importance of BRCA] in sporadic breast
cancer with LOH on 17q21 is still controversial (Futreal et
al., 1994).
The objective of the present study was to investigate the
involvement of the chromosomal region 13ql2-ql4,
comprising the BRCA2 and RB] loci, and its possible
clinical importance in breast cancer. In accordance with the
findings at BRCAI, a similarly high frequency (>30%) of
LOH was found at BRCA2 in sporadic, familial and
hereditary tumours. Moreover, not only was the frequency
of LOH lower at RB], but the relationship to aggressive
tumour phenotype (high proliferation, autonomous growth,
genetic instability, etc.) and poor prognosis was more or less
confined to tumours manifesting allelic loss at BRCA2, with
or without concomitant loss of RB]. This implies that
BRCA2, or an additional adjacent gene other than RB], is
the likely target for 13q deletions in breast cancer, in keeping
with our earlier observations of a lack of association between
LOH at RB] and loss of pRB expression (Borg et al., 1992).
Strong evidence for the inactivation of BRCA2 via the
postulated two-hit mechanism was recently provided in
studies of breast cancer and other tumours from disease
haplotype carriers of a BRCA2-linked family, demonstrating
a preferential loss of the wild type allele (Collins et al., 1995;
Gudmundsson et al., 1995). In the present study, information
on BRCA2 linkage and/or germline mutations was available
only for a subset of familial and hereditary cases. In one of
the hereditary cases included (Lund 11), a single basepair (G)
deletion at nucleotide 4486 in exon 11 of BRCA2 has been
identified (Hakansson et al., submitted), creating a premature
termination at codon 1447. The tumour from Lund 11
(no.8648) did, indeed, manifest LOH at BRCA2 and also at
RBI. In 12 of the remaining 36 familial and hereditary cases
of the present study, screening of all exons in BRCA2 was
performed, giving no further evidence of germline mutations.
Only in 2 of these 12 cases was LOH at the BRCA2 locus
present. Germline BRCA] mutations have previously been
described (Johannsson et al., 1996) in three of the cases
included in the present study (Lund 33, 44 and 56); a fourth
case manifested clear BRCA] linkage (Lund 1). In two of
these four cases LOH was present in all informative 13q
markers, whereas one case manifested retained heterozygosity
at the BRCA2 locus. Interestingly, in the fourth case (no.6814
from Lund 33), LOH was seen at D13S219 and D13S263 but
not at the BRCA2 and RBI loci, implying the existence of an
additional gene of importance in the 13ql2-ql4 region,
telomeric of BRCA2 and centromeric of RBI (Figure 1).
Restricted LOH at a region centromeric of BRCA2 was also
observed, suggesting the presence of other putative tumour
suppressor genes. Obviously, Brush-] may be one such gene
as it is affected by deletion and reduced expression in
tumours without alterations at RBI (Schott et al., 1994). The
presence of at least three tumour-suppressor genes in the
13ql2-ql4 region may explain why extensive deletions, or
even the loss of a whole chromosome 13, are common and
selected for in breast cancer (Devilee et al., 1989). One
previous investigation of sporadic breast cancer and
alterations in the 13ql2-ql4 region demonstrated allelic
loss in 32% of 200 tumours and a simultaneous loss of both
the BRCA2 and RBI loci in all cases (Cleton-Jansen et al.,
1995), whereas another report has pointed out the restricted
involvement of the BRCA2 loci in some tumours
(Kerangueven et al., 1995).
The finding of the near complete loss of one allele (merely
a faint band visible, presumably representing DNA from
normal tissue within the tumour) in a considerable
proportion of tumours suggests that 13q deletion is an early
step in tumour development. Additionally, loss of a 13ql2-
q14 gene may confer a strong growth advantage to the cell,
resulting in a selective outgrowth ofcell clones which harbour
the losses. Furthermore, the strong correlation between LOH
and high S-phase fraction values indicates the inactivation of
a gene (or several genes) involved in cell cycle control. It is
unlikely that these associations are due to a general genomic
instability, as there was no correlation between LOH at
chromosome 13q and 16q, and as the latter alteration was
unrelated to prognosis. However, the present study provides
no proof that the association with aggressive tumour
behaviour is specifically as a result of inactivation of the
BRCA2 gene. Certainly, in a parallel study of biological
tumour features from individuals with germline BRCA]
mutations or manifesting clear BRCA] linkage, a relation-
ship to aggressive phenotype and rapid proliferation has been
noted (Johannsson et al., submitted). This implies that a
functional similarity between these breast cancer suscept-
ibility genes may exist and that their inactivation initiates a
dedifferentiated state and a certain genetic pathway, leading
to rapid tumour progression. Although we have seen only a
tendency towards a worse prognosis in BRCAI-induced
1618
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breast cancer (Johannsson et al., submitted), LOH at the
chromosomal region comprising the BRCA2 gene was
strongly and independently correlated to early recurrence
and death. This association was evident in both familial and
hereditary tumours as well as in sporadic tumours, suggesting
that alterations of the putative target gene constitutes a new
prognostic factor of potential clinical importance.
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